Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease

Reuters

Jul 31

Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease

Soligenix Inc., a late-stage biopharmaceutical company, has announced the completion of its Phase 2a proof of concept study evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease. The study aimed to assess the biological efficacy of SGX945 in addressing aphthous ulcers associated with the condition. Results demonstrated biological efficacy, with 7 out of 8 patients showing benefits from the treatment. The open-label study involved administering SGX945 through a twice-weekly intravenous infusion over four weeks, followed by a four-week follow-up period. The outcomes support the potential advancement of SGX945 in treating this challenging orphan disease, and further placebo-controlled studies are anticipated to explore its full benefits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH41118) on July 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555887041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555887041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555887041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555887041","market":"us","top_or_hot":-1,"title":"Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soligenix Inc., a late-stage biopharmaceutical company, has announced the completion of its Phase 2a proof of concept study evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease. The study aimed to assess the biological efficacy of SGX945 in addressing aphthous ulcers associated with the condition. Results demonstrated biological efficacy, with 7 out of 8 patients showing benefits from the treatment. The open-label study involved administering SGX945 through a twice-weekly intravenous infusion over four weeks, followed by a four-week follow-up period. The outcomes support the potential advancement of SGX945 in treating this challenging orphan disease, and further placebo-controlled studies are anticipated to explore its full benefits.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH41118) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soligenix Inc., a late-stage biopharmaceutical company, has announced the completion of its Phase 2a proof of concept study evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease. The study aimed to assess the biological efficacy of SGX945 in addressing aphthous ulcers associated with the condition. Results demonstrated biological efficacy, with 7 out of 8 patients showing benefits from the treatment. The open-label study involved administering SGX945 through a twice-weekly intravenous infusion over four weeks, followed by a four-week follow-up period. The outcomes support the potential advancement of SGX945 in treating this challenging orphan disease, and further placebo-controlled studies are anticipated to explore its full benefits.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH41118) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL9M7Ntc:1","article_id":"2555887041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555887041","pubTimestamp":1753961522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Soligenix Inc., a late-stage biopharmaceutical company, has announced the completion of its Phase 2a proof of concept study evaluating SGX945  for the treatment of Behet's Disease. The study aimed to assess the biological efficacy of SGX945 in addressing aphthous ulcers associated with the condition. Results demonstrated biological efficacy, with 7 out of 8 patients showing benefits from the treatment. The open-label study involved administering SGX945 through a twice-weekly intravenous infusion over four weeks, followed by a four-week follow-up period. The outcomes support the potential advancement of SGX945 in treating this challenging orphan disease, and further placebo-controlled studies are anticipated to explore its full benefits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNGX":"Soligenix, Inc."},"translate_title":"Soligenix Inc.宣布SGX945治疗贝赫切特病的2期试验结果成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNGX":0.9},"content_text":"Soligenix Inc. Announces Successful Phase 2 Trial Results for SGX945 in Treating Behçet's Disease\n    \n\n        Soligenix Inc., a late-stage biopharmaceutical company, has announced the completion of its Phase 2a proof of concept study evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease. The study aimed to assess the biological efficacy of SGX945 in addressing aphthous ulcers associated with the condition. Results demonstrated biological efficacy, with 7 out of 8 patients showing benefits from the treatment. The open-label study involved administering SGX945 through a twice-weekly intravenous infusion over four weeks, followed by a four-week follow-up period. The outcomes support the potential advancement of SGX945 in treating this challenging orphan disease, and further placebo-controlled studies are anticipated to explore its full benefits.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH41118) on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}